Drugs / MabCampath-1h
last change Sep 2018 re-read 3 minutes ago

MabCampath-1h

Developed for
relapsing-remitting multiple sclerosis
Investigated by
Genzyme, a Sanofi Company · University of British Columbia

Trials 1

20112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 3 NCT01307332 Mar 2011 → Sep 2018 relapsing-remitting multiple sclerosis University of British Columbia Completed No outcome recorded

Evidence & citations 1 cited value

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as MabCampath-1h ClinicalTrials.gov intervention name — accepted as the source's own label NCT01307332 ↗